Genitourinary Cancers

11 protocols meet the specified criteria.
  • APL-101-01

    Phase 1 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Advanced Solid Tumors and c-Met Dysregulation
  • DB-020-002

    Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeated Doses of DB-020 in Patients Receiving Cisplatin
  • EAY131

    Molecular Analysis for Therapy Choice (MATCH)
  • INCB54828-207

    A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants with Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
  • NRG-GU002

    Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prosatectomy with or without Adjuvant Docetaxel.
  • NRG-GU005

    Phase III IGRT and SBRT versus IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
  • S1602

    A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T-Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-Muscle Invasive Bladder Cancer
  • SIMPRO

    SIMPRO Research Center: Integration and Implementation of PROs for Symptom Management in Oncology Practice.
  • WVU011118

    Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry
  • WVU011119

    Epigenetic Characterization of Radiation Exposure
  • WVU021119

    Evaluation of the Epigenetic Effects of Circulating DNA Methyltransferases and Histone Deacetylase Levels to Predict Toxicity from Radiation Therapy